(1-(tert-Butoxycarbonyl)-5-((4,4-dimethoxypiperidin-1-yl)methyl)-1H-indol-2-yl)boronic acid

Catalog No. :
ACWRHM349
CAS No. :
913388-69-9
Molecular Formula :
C21H31BN2O6
Molecular Weight :
418.30

IUPAC Name:(1-(tert-butoxycarbonyl)-5-((4,4-dimethoxypiperidin-1-yl)methyl)-1H-indol-2-yl)boronic acid

(1-(tert-Butoxycarbonyl)-5-((4,4-dimethoxypiperidin-1-yl)methyl)-1H-indol-2-yl)boronic acid structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(1-(tert-Butoxycarbonyl)-5-((4,4-dimethoxypiperidin-1-yl)methyl)-1H-indol-2-yl)boronic acid
IUPAC Name(1-(tert-butoxycarbonyl)-5-((4,4-dimethoxypiperidin-1-yl)methyl)-1H-indol-2-yl)boronic acid
Molecular FormulaC21H31BN2O6
Molecular Weight418.30
SMILESO=C(N1C(B(O)O)=CC2=C1C=CC(CN3CCC(OC)(OC)CC3)=C2)OC(C)(C)C
InChI KeyPFVDVTKMMZFCJR-UHFFFAOYSA-N
Synonym1H-Indole-1-carboxylic acid, 2-borono-5-[(4,4-dimethoxy-1-piperidinyl)methyl]-, 1-(1,1-dimethylethyl) ester;PFVDVTKMMZFCJR-UHFFFAOYSA-N
CAS No.913388-69-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319
Precautionary Statement(s)
P264-P270-P280-P301+P312+P330-P302+P352-P305+P351+P338-P332+P313-P337+P313-P362+P364-P501

Synthetic Route by SureRoute

1. ACWRHM349 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACWRHM349 route product structure diagram
    ACWRHM349913388-69-9
Inquiry

2. ACWRHM349 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACWRHM349 route product structure diagram
    ACWRHM349913388-69-9
Inquiry

Comments (0)